Souhaitez-vous accéder aux communiqués récents ?

MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the...

MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC) by Health Canada for the prevention of...

EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease...

MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual...

EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery...

Executive summary first biocompatible pharmaceutical formulations progress to preclinical modelsnew sustained-release drug delivery platforms for peptides, melanocortinsaim to predict drug release...

Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025CLINUVEL’s primary listing on the ASX will...

CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11,...

CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).